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OBJECTIVES The effect of patient age on circulating endothelial progenitor cells (EPCs) and their
mobilization during coronary artery bypass grafting (CABG) was assessed.
BACKGROUND The EPCs are able to contribute to reparative neovascularization after tissue ischemia. In
experimental models, reparative neovascularization is impaired in senescent animals, but the
role of EPCs in this impairment, especially in humans, is unknown.
METHODS In 50 consecutive patients (43 to 80 years old) with stable coronary artery disease undergoing
CABG, the numbers of EPCs and the plasma levels of interleukin (IL)-6, IL-8, IL-10, and
IL-18, as well as vascular endothelial growth factor (VEGF) and placental growth factor,
were determined preoperatively, after coming off bypass, and 6, 12, 24, and 72 h
postoperatively.
RESULTS Preoperative values of EPCs were lowered with increasing age, similar to the lowering of
plasma VEGF levels. These age-associated decreases could not be explained by differences in
atherosclerotic risk factors or cardiac function. Bypass surgery induced a rapid mobilization in
EPCs, IL-6, IL-8, IL-10, and VEGF, with a peak 6 h postoperatively. Persistently lower
levels of EPCs and VEGF throughout the observation period were observed in patients 69
years old, which could not be explained by differences in the operative procedure or
inflammatory IL activation.
CONCLUSIONS Despite a significant increase in EPCs and release of cytochemokines during CABG, age is
a major limiting factor for mobilization of EPCs. Further studies are necessary to improve the
strategies for mobilization, ex vivo expansion, and re-transplantation of EPCs in aging
patients. (J Am Coll Cardiol 2003;42:2073–80) © 2003 by the American College of
Cardiology Foundation
Coronary artery bypass grafting (CABG) or percutaneous
transluminal coronary angioplasty (PTCA) is used to recon-
stitute flow into post-stenotic, chronically underperfused
myocardium. This post-stenotic myocardium consists of
connective tissue scars, dying cardiomyocytes, and hypo-
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active or chronically hibernating myocardium with micro-
vascular disturbances due to microthrombi and decreased
capillary density (1). When bulk flow is successfully recon-
stituted by CABG or PTCA, the gradual recovery of micro-
circulation is considered as decisive for the recovery of mechan-
ical function of surviving post-stenotic myocardium (2).
Traditionally, neovascularization of disturbed microcircu-
lation was considered to result exclusively from the prolif-
eration, migration, and remodeling of fully differentiated
endothelial cells (ECs) derived from pre-existing blood
vessels (3). Recently, however, it was demonstrated that
circulating, bone marrow-derived endothelial progenitor
cells (EPCs) may home to sites of postnatal neovasculariza-
tion and differentiate into ECs in situ (4), which is called
“vasculogenesis” (5). Vascular trauma, as it occurs during
surgical procedures, or inflammation leads to a cascade of
events that result in the chemoattraction of inflammatory
cells or other cell types to the site of injury (6). These
blood-borne cells produce pro-angiogenic factors that, in
turn, attract other cell types such as circulating EPCs (7).
Systemic inflammatory responses have been described after
cardiac surgery with cardiopulmonary bypass (CPB) (8).
Contact of the blood components with the artificial surface
of the extracorporeal circuit, ischemia-reperfusion injury,
endotoxemia, and operative trauma are possible causes for
this phenomenon (8). Trauma has been considered as the
critical stimulus for the mobilization of EPCs and pro-
angiogenic vascular endothelial growth factor (VEGF) dur-
ing CABG (9). It has been speculated that this mobilization
may contribute to the revascularization of injured tissue (9),
which would be of great clinical relevance for a successful
outcome of CABG.
Presently, there is a strong trend to perform CABG in
patients of advanced age (10). However, experimental data
indicate impaired neoangiogenesis in ischemic tissues and
impaired re-endothelialization of vascular lesions as a func-
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tion of advanced age (11–13). The mechanisms for this
age-dependent impairment of vascular repair are largely
unknown. Therefore, we analyzed the influence of age on
CABG-induced mobilization of EPCs and cytochemokines
with angiogenesis-modulating potential in a cohort of
consecutive patients with stable coronary artery disease
(CAD) scheduled for elective CABG. Probably, several
types of endothelial precursor or progenitor cells have
angiogenic potential after homing into traumatic tissue
(14–18). Therefore, we used two phenotypic markers
(CD34 [19] and AC133 or CD133 [20]), which are
expressed in all EPC types, but in the case of AC133, not in
differentiated ECs (15,17,21). This was done to exclude
from our analysis any mature or dying ECs with doubtful
angiogenic capacity, potentially released from damaged
vessels in old patients.
In this analysis, we demonstrate that the preoperative
number of circulating EPCs in patients with stable CAD is
reduced with increasing age, together with decreased plasma
VEGF levels. During CABG, mobilization of circulating
EPCs could be detected in all patients, but this mobilization
remained on a persistently lower level in the older patient
group, suggesting that the responsiveness for mobilization
of EPCs is impaired with age. Optimized strategies for ex
vivo expansion of those cells might be especially required in
the elderly, if transplantation of these cells into post-
stenotic tissue will develop as a future co-therapy to existing
interventions of revascularization.
METHODS
After approval by the local ethics committee of the Univer-
sity of Halle-Wittenberg, 50 consecutive patients with
angiographically documented one-, two-, or three-vessel
Abbreviations and Acronyms
APC  allophycocyanin
CABG coronary artery bypass grafting
CAD  coronary artery disease
CPB  cardiopulmonary bypass
EC  endothelial cell
EPC  endothelial progenitor cell
KDR  kinase insert domain containing receptor
IL  interleukin
PlGF  placental growth factor
PTCA  percutaneous transluminal coronary angioplasty
VEGF  vascular endothelial growth factor
Table 1. Baseline Characteristics and Perioperative Data of Patients
Data
All Patients
43–80 Yrs
(n  50)
Patients
<62 Yrs
(n  14)
Patients
62–69 Yrs
(n  19)
Patients
>69 Yrs
(n  17)
Risk factors, n (%)
Male gender 37 (74) 11 (79) 17 (90) 9 (53)
Diabetes mellitus 19 (38) 5 (36) 8 (42) 6 (35)
Hypertension 45 (90) 11 (79) 17 (90) 17 (100)
Nicotine abuse 22 (44) 11 (79) 7 (37) 4 (24)
Hyperlipoproteinemia 42 (84) 11 (79) 17 (90) 14 (82)
LVEF (%) 62.1  2.0 61.2  4.6 63.4  2.3 61.4  3.9
NYHA class, n (%)
I 5 (10) 2 (14) 2 (11) 1 (6)
II 37 (74) 11 (79) 14 (74) 12 (71)
III 6 (12) 1 (7) 2 (11) 3 (18)
IV 2 (4) 0 1 (5) 1 (6)
Operative data
CPB time (min) 105  5 107  7 98  6 112  11
Cross-clamping time (min) 58  3 61  4 53  4 60  5
No. of grafts 3.4  0.1 3.4  0.2 3.6  0.1 3.2  0.2
EPCs
EPCs/100,000 lymphocytes 41.9  3.7 58.6  9.5 36.2  5.1 34.5  3.4*
EPCs/100 l blood 79.1  7.3 118.2  14.4 71.0  11.9* 58.8  8.1*
Lymphocytes/leukocytes (%) 32.9  1.4 34.6  3.1 32.5  2.5 32.0  2.1
Leukocytes (1,000/l blood) 6.0  0.3 6.4  0.5 6.3  0.6 5.3  0.3
Plasma cytochemokines (pg/ml)
IL-6 3.5  1.1 2.0  0.7 5.6  2.9 2.5  0.5
IL-8 4.8  0.6 4.1  1.0 5.2  1.4 4.9  0.8
IL-10 3.0  0.7 5.2  1.9 2.7  0.8 1.5  0.5
IL-18 275  20 249  33 264  32 312  39
VEGF 22.1  2.2 33.4  6.0 18.7  1.7* 15.7  2.5*
PlGF 15.7  1.4 17.2  4.1 14.4  1.3 16.1  2.1
Reported significances (*p  0.05) for the respective parameters result from Bonferroni-adjusted t tests of comparing age groups
62 and 69 years, as well as 62 and 62 to 69 years. Data are presented as the number (%) of patients or mean value  SD.
CPB  cardiopulmonary bypass; EPC  endothelial progenitor cells; IL  interleukin; LVEF  left ventricular ejection
fraction; NYHA New York Heart Association; PlGF placental growth factor; VEGF vascular endothelial growth factor.
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CAD gave written, informed consent and were enrolled in
this prospective study. The patient characteristics are sum-
marized in Table 1. Exclusion criteria were as follows:
re-operation for CABG; children; pregnancy; coumarin
anticoagulant treatment; coagulopathy; liver dysfunction;
nephropathy with dialysis; medication with immune-
modulating agents such as steroids and anti-inflammatory
agents; any history or signs of infectious disease before
surgery; re-animation or revision after CABG; and implan-
tation of an intra-aortic balloon pump or ventricular assist
device. All patients underwent nonemergent CABG and
received the same intravenous anesthesia, consisting of
sufentanil (Sufenta, Janssen-Cilag, Neuss, Germany),
propofol (Disoprivan, AstraZeneca, Wedel, Germany), and
midazolam (Dormicum, Roche, Grenzach-Wyhlen, Ger-
many) under a standardized protocol. The CPB circuit
consisted of roller pumps (Stoeckert, Mu¨nchen, Germany),
a membrane oxygenator (CML Duo, Cobe, Arvada, Colo-
rado), a hard-shell venous reservoir (Cobe), and a 43-m
arterial filter (Cobe Sentry). Full-dose heparin (350 U/kg;
Liquemin N 25000, Hoffmann-La Roche, Grenzach-
Wyhlen, Germany) was applied before cannulation of the
ascending aorta and right atrium for installation of CPB.
Aprotinin (Trasylol, Bayer, Leverkusen, Germany) was
given at dosage of 3  106 U to all patients. Induction of
heart arrest was performed by the use of cold crystalloid
cardioplegia (Bretschneider-HTK, Ko¨hler, Alsbach, Ger-
many), intermittent cold blood cardioplegia, or intermittent
normothermic blood cardioplegia. After coming off bypass,
the patient was given protamine (Protamin ICN 1000
I.E./ml, ICN, Frankfurt/Main, Germany) to neutralize the
heparin dosage to 100%.
The blood samples were taken in heparinized tubes at six
time points for each patient as follows: sample 1, 10 min
before induction of anesthesia; sample 2, after coming off
bypass; sample 3, in the intensive care unit 6 h after surgery;
sample 4, in the ICU 12 h after surgery; sample 5, 24 h after
surgery; and sample 6, 72 h after surgery. All blood samples
were evaluated by flow cytometry within 24 h or immedi-
ately spun at 1,000 g for 15 min. The plasma was separated
and frozen at 20°C.
Flow cytometric analysis. A volume of 100 l peripheral
blood was incubated for 15 min with 2 ml of 1 ammonium
chloride lysing solution (Becton Dickinson, Heidelberg,
Germany). After centrifugation at 500 g, the cells were
resuspended in 100 l buffer (containing 45 ml RPMI-1640
cell culture medium, 5 ml bovine calf serum, and 500 l 3%
NaN3) and incubated for 30 min in the dark with fluores-
cein isothiocyanate-labeled monoclonal antibodies against
human CD34 (Becton Dickinson) and allophycocyanin
(APC)-labeled monoclonal antibodies against human
AC133 (Miltenyi Biotec, Bergisch Gladbach, Germany).
Isotype-identical antibodies served as controls (Becton
Dickinson). After incubation, cells were washed with 2 ml
washing solution (Becton Dickinson), centrifuged at 500 g
for 5 min, and resuspended in 500 l washing solution
(Becton Dickinson). Before each analysis, 7-amino-
actinomycin-D was added as a viability stain. Each analysis
included 100,000 events within the lymphocyte gate. Thus,
we obtained the number of EPCs per 100,000 lymphocytes
(EPC/lymphocytes) and, after adjustment for the number of
leukocytes in peripheral blood and the fraction of lympho-
cytes/leukocytes, the number of EPCs per 100 l blood
(EPC/blood). Representative examples of these flow cyto-
metric analyses are shown in Figures 1a to 1f.
Functional characterization of CD34 and AC133 pro-
genitor cells. The endothelial differentiation potential of
these progenitor cells was assessed by analyzing the expres-
sion of EC-specific markers after incubation for three days
in an endothelial growth medium (EGM-2, BioWhittaker,
Verviers, Belgium) on fibronectin-coated culture dishes
(Becton Dickinson). Human CD34 cells were isolated
from “buffy coats” of donor blood via immunomagnetic
CD34 microbead extraction (Miltenyi Biotec), according
to the manufacturer’s instructions, and analyzed by flow
Figure 1. Representative dot blot flow cytometric analysis of the mobilized
endothelial progenitor cells/lymphocytes, quantifying the number of CD34
and AC133 cells in the older (69 years) and younger patients (62
years) preoperatively (c, d) and 6 h after surgery (e, f), together with isotype
control of older (a) and younger patients (b). APC  allophycocyanin;
FITC  fluorescein isothiocyanate.
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cytometry for AC133-APC (Miltenyi Biotec), AcLDL-
DiI binding (Paesel & Lorei, Hanau, Germany),
vascular/endothelial-cadherin-phycoerythrin (Santa Cruz,
Heidelberg, Germany), and kinase insert domain containing
receptor (KDR) (ReliaTech, Braunschweig, Germany), vi-
sualized using APC-conjugated rat anti-mouse monoclonal
antibody (Becton Dickinson). Viable double-positive
CD34/AC133 cells had a mean fluorescence due to AcLDL
binding of 30.0 relative units (rU), which increased to 100.2
rU after 3 days of differentiation in EGM-2, a mean
fluorescence of VE-cadherin of 3.7, which increased to 32.7
rU, and a mean florescence of KDR of 65.4 rU, which
increased to 457.3 rU. This differentiation potential of
CD34/AC133 progenitor cells toward an endothelial
phenotype, documented representatively, justifies their de-
nomination as EPCs. However, the functional characteriza-
tion of CD34/AC133 cells was not performed in all
investigated samples of patients. As the true differentiation
of CD34/AC133 cells toward an endothelial phenotype
can be proved only in vivo, our investigation was an analysis
of CD34/AC133 progenitor cells, which should have the
potential to differentiate toward an endothelial phenotype.
Plasma VEGF, placental growth factor (PlGF), interleu-
kin (IL)-6, IL-8, IL-10, and IL-18 levels. Quantitative
determination of the cytokine plasma levels of patients was
performed in duplicate by a highly sensitive enzyme-linked
immunosorbent assay (R&D Systems, Wiesbaden, Ger-
many), according to the manufacturer’s instructions. Sam-
ples were analyzed in a FLUOstar OPTIMA (BMG,
Offenburg, Germany).
Statistical analysis. For statistical analysis, standard meth-
ods were used, as indicated in the figure legends and
tables—for example, Pearson’s correlation coefficient
(Fig. 2) (see Results section), repeated measures analysis of
variance (ANOVA) models (Figs. 3, 4, and 5), ordinary
ANOVA models (Fig. 5), linear regression (Table 2) (see
Results section), and t tests (Table 1). Pairwise comparisons
were Bonferroni-adjusted to avoid spurious significances.
Calculations were performed by SAS version 8e (SAS
Institute Inc., Cary, North Carolina).
RESULTS
Patients. The characteristics of the 50 consecutive patients
with elective CABG (median age 65 years, range 43 to 80
years) are presented in Table 1, together with basal circu-
lating EPC values and plasma cytochemokine levels. The
patients were classified into three age groups:62, 62 to 69,
and 69 years old. In patients of advanced age, the number
of circulating EPCs/lymphocytes, as well as EPCs/blood,
and VEGF plasma levels were significantly reduced. These
values showed a negative correlation with age (Figs. 2a to
2c). Furthermore, there was an age-independent correlation
of VEGF with EPCs/lymphocytes (p  0.002) and with
EPCs/blood (p  0.001). Basal EPC values did not
correlate with other risk factors (Table 2), with the cumu-
lative number of risk factors, or with any other plasma
cytochemokine level. The association between age and EPC
values persisted even after adjustment for risk factors in a
linear regression model (Table 2).
Mobilization of EPCs and induction of cytochemokines
by CABG. After CPB, there was a biphasic response of
EPC values (Fig. 3). The first phase consisted of an increase
in EPCs/lymphocytes, 1.5-fold at the end of CPB and
2-fold 6 h later, relative to the preoperative baseline value,
respectively (Fig. 3a). Concomitantly, we observed a two-
fold increase in leukocytosis (Fig. 3b) and a progressive
decline in the fraction of lymphocytes/leukocytes (Fig. 3c).
These alterations resulted in a two-fold increase in circulat-
ing EPCs/blood at the end of CPB, which returned to basal
levels 6 h later (Fig. 3d). The EPCs/lymphocytes transiently
returned to or below preoperative levels one day after
surgery (Fig. 3a), whereas the fraction of lymphocytes/
leukocytes and circulating EPCs/blood declined below
baseline levels (Figs. 3c and 3d). The second phase of
increase in EPCs/lymphocytes occurred three days later
(Fig. 3a), whereas the leukocytosis remained elevated
throughout this period (Fig. 3b).
Figure 2. Age-dependent decrease of preoperative endothelial progenitor
cells (EPC) values (a, b) and plasma vascular endothelial growth factor
(VEGF) level (c) in patients undergoing coronary artery bypass graft
surgery. The Pearson correlation coefficient and p values of the correspond-
ing significance test of the respective values are indicated.
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An apparently similar biphasic response could be ob-
served for plasma levels of VEGF and IL-10 (Fig. 4a). After
a first increase 6 h postoperatively (2.6-fold for VEGF and
10.7-fold for IL-10), both plasma levels declined transiently
after one day, but the second phase of increase after 3 days
did not reach the level of significance relative to the previous
values (Fig. 4a). The pro-inflammatory cytokines IL-6 and
IL-8 showed a monophasic response, a 50-fold increase for
IL-6, and a 10-fold increase for IL-8 after 6 h (Fig. 4b). In
addition, the increase of IL-6 after 6 h correlated signifi-
cantly with the time on CPB (p  0.009). For PlGF and
IL-18, postoperative plasma levels did not change signifi-
cantly relative to preoperative values (Fig. 4c).
In the first phase of the surgery-induced increase in EPC
values, the increase in EPCs/lymphocytes showed a negative
age dependency (r  0.307, p  0.03). However, the
increase in neither EPCs/blood nor EPCs/lymphocytes
correlated with any other risk factor, New York Heart
Association classification, or operative data. Furthermore,
there was no positive correlation of the increases in EPC
values with any of the operation-induced increases in plasma
cytochemokines.
In the three age groups, the biphasic response of EPCs/
lymphocytes and EPCs/blood was similar, but this response
remained at significantly higher levels in the younger group
compared with the older patients throughout the observa-
tion period (Figs. 5a and 5b). In plasma VEGF, the oldest
patient group had a retarded response, with significantly
lower values 6 h after the end of CPB, compared with
younger patients, and significantly lower values throughout
the observation period (Fig. 5c).
DISCUSSION
This study demonstrates that the basal number of circulat-
ing EPCs in patients with stable CAD is decreased with
increasing age. Furthermore, plasma VEGF levels are re-
duced with increasing age. This age-associated decrease
could not be explained by higher prevalences of other risk
factors, such as male gender, diabetes mellitus, hyperten-
sion, or hyperlipoproteinemia at older ages (Table 2), nor by
any differences in left ventricular function or New York Heart
Association classes. The operative trauma of complex cardiac
surgery with CPB induced a mobilization in EPCs/
lymphocytes and EPCs/blood in all patients, but this mobili-
zation remained on a persistently lower level in the older
patient group, which could not be explained by any differences
in the operative procedure (time on CPB, cross-clamping time,
Figure 3. Mobilization of endothelial progenitor cells (EPC) and leuko-
cytes by coronary artery bypass graft surgery. Reported significances (*p 
0.05, **p  0.01, ***p  0.001) were calculated by Bonferroni-adjusted
pairwise comparisons with the preoperative level within a repeated mea-
surement analysis of variance model for the respective parameter at five
different time points. CPB  cardiopulmonary bypass.
Figure 4. Induction of cytochemokines by coronary artery bypass graft
surgery. Reported significances (*p  0.05, **p  0.01, ***p  0.001) were
calculated by Bonferroni-adjusted pairwise comparisons with the preoper-
ative level within a repeated measurement analysis of variance model for
the respective parameter at three different time points. IL  interleukin;
PlGF  placental growth factor; VEGF  vascular endothelial growth
factor.
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or number of grafts) or in the operation-induced increase in
cytochemokines with a reported potency for modulation of
angiogenesis (IL-6, IL-8, and IL-10).
To the best of our knowledge, similar age-associated
losses in the number of circulating endothelial-related
progenitor cells in patients undergoing CABG have not
been reported so far. In 45 male subjects without a history
of cardiovascular disease, the Framingham risk score and
impairment of endothelium-mediated, flow-dependent bra-
chial artery dilation were strong predictors of depressed
numbers in circulating progenitor cells with colony-forming
capacity (22). In a mixed group of healthy probands and
CAD patients, Vasa et al. (23) reported age-associated
losses in circulating cells positive for CD34 and KDR,
which may include progenitor cells and mobilized ECs (21).
In their cohort, smoking was a strong predictor of lowered
values in CD34/KDR cells, independent of age (23). In
our patients, self-reported smoking status, which is notori-
ously unreliable before cardiac surgery, could not be verified
by interrogations of spouses or relatives. This may explain
why we could not detect an effect of smoking on circulating
EPCs.
The reasons for the age-associated losses in circulating
EPCs remain unknown at present. In our study, there was
an age-independent correlation of circulating EPCs with
plasma VEGF levels. Circulating or transplanted EPCs
contribute to post-ischemic neovascularization in animal
experiments (4,7,24,25) and patients (26,27), and angio-
genic factors like VEGF and PlGF are involved in this
neovascularization (28–31). In animals, advanced age is
associated with attenuated post-ischemic neovascularization
and attenuated local induction of VEGF (12,13,32). Simi-
larly, arterial re-endothelialization after vascular trauma is
attenuated in old animals in which trauma-induced local
VEGF expression is lower and local VEGF supplementa-
tion rescues vascular healing (11). Experimental elevation of
plasma VEGF in mice by inoculation with adenoviral
vectors induced rapid mobilization of endothelial precursor
cells (9). Therefore, it is tempting to propose that lowered
VEGF levels in our elderly patients are the reason for
lowered circulating EPCs. However, this causality remains
to be proven for basal steady-state levels, and the cause of
depressed circulating VEGF levels in elderly patients re-
mains unknown. In experimental studies, hypoxia-inducible
factor-1 stabilization by hypoxia, which mediates hypoxic
VEGF expression, is attenuated in cells from old animals
(12). This might be relevant for the attenuated and retarded
CABG-induced activation of plasma VEGF in older pa-
tients (Fig. 5). However, this may be less relevant for the
age-associated lowering in basal VEGF levels before surgery.
Local and systemic inflammation by vascular trauma is
considered an important contributor of post-ischemic neo-
vascularization (33). In our patients, the operative trauma
resulted in a substantial mobilization of cytochemokines
with angiogenesis-modulating potential (28,31,34–37), ex-
cept for IL-18 and PlGF (Fig. 4). These observations are in
agreement with previous reports (38–40). Although none
of these activated factors could be directly correlated with
the individual increase in EPCs during and after the
operation in our patients, it is reasonable to assume that the
complex spectrum of inflammatory activation is contribut-
ing to the mobilization of surgery-induced EPCs. Similar
conclusions have been derived from observations on tran-
sient mobilization of KDR/AC133 cells in patients after
burns or CABG (9). The kinetics of mobilization in that
study differed somewhat from our observations, but the two
studies are not directly comparable owing to differences in
progenitor cell analysis (9). It is remarkable that the sub-
stantial inflammatory activation during surgery in our study
could not abolish age-associated differences in EPC levels.
The decline in the fraction of lymphocytes/leukocytes
after CPB down to one-quarter that of the baseline value at
12 h after CPB (Fig. 3c) most likely reflects substantial
Figure 5. Age dependency of endothelial progenitor cells (EPCs)/
lymphocytes (a), EPCs/blood (b), and vascular endothelial growth factor
(VEGF) (c) after coronary artery bypass graft surgery. The global age
effects (EPCs/lymphocytes: p  0.01; EPCs/blood: p  0.01; VEGF: p 
0.05) between the two age groups62 and69 years were assessed within
a repeated measures analysis of variance model also adjusting for time.
Reported significances (*p  0.05) for VEGF between the two age groups
62 and 69 years at the time points preoperatively and 6 h postoperatively
were calculated by separate (for each time point) analysis of variance models.
The three comparisons between the age groups at each time point were
Bonferroni-adjusted. Circles62 years; squares 62 to 69 years; triangles
 69 years.
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homing of lymphocytes into tissues in response to the
systemic inflammatory activation induced by CPB. Homing
must also contribute to the decline of circulating EPCs/
blood during this time (Fig. 3d). Therefore, circulating
EPC levels underestimate the amount of EPC mobilization.
However, quantification of lymphocyte or EPC homing
could not be obtained in our patients.
Application of different populations of EPCs or other
mononuclear bone marrow cells improves postischemic
organ function and microcirculation in animals and patients
(16,24–27,41,42). However, it is not clear whether the
surgery-induced mobilization of EPCs is sufficient for such
a contribution. Furthermore, it is unclear whether the EPCs
in elderly patients have the same angiogenic potential
compared with those of younger patients. The EPCs
collected from the circulation can be amplified in vitro
(24,26). The co-application of amplified EPCs, together
with native artery recanalization or bypass grafting, probably
will develop as a therapeutic option in the future. The
experimental data (12,13,32) suggest that such co-therapy is
especially desirable in elderly patients. Our data suggest that
mobilization of such cells for therapeutic application might
be more difficult with an increasing age of patients.
Conclusions. Application of EPCs might expand the tools
for therapeutic revascularization and regeneration. How-
ever, this potential future strategy seems to be aggravated in
aging patients because of lowered numbers of EPCs and
lowered VEGF plasma levels. The inflammatory activation
by complex CABG does not offset this age-associated
lowering. Therefore, further studies are required for a better
understanding of optimized strategies for recruitment, ex
vivo expansion, and retransplantation strategies involving
EPCs in aging patients.
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